GNRH AGONIST TEST

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 为了检验对注射挑战剂量的促性腺激素释放激素激动剂(GnRHag)的激素反应将区分青春期障碍以及睡眠测试的总体假设。具体地说，我们将测试注射促性腺激素释放激素激动剂醋酸亮丙瑞林的反应将区分性早熟和青春期延迟的原因以及荷尔蒙睡眠测试的假设。对青春期疾病的及时诊断存在障碍：1)低利润药物的生产削减导致经常无法获得用于测试目的的天然促性腺激素释放激素(Factrel)，2)尚未为当前一代高度敏感和特定的促性腺激素和性类固醇分析建立儿童正常和诊断标准，以及3)科学进步导致了潜在的新的诊断结果衡量标准。该项目比较了患有青春期障碍的儿童和健康儿童对照组。主要的结果指标是平均的黄体生成素对睡眠的反应，与对GnRHag醋酸亮丙瑞林的黄体生成素峰值反应进行比较。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To test the overall hypothesis that the hormonal responses to injection of a challenge dose of GnRH agonist (GnRHag) will distinguish among disorders of puberty as well as a sleep test. Specifically, we will test the hypotheses that the response to injection of the GnRH agonist leuprolide acetate will distinguish among the causes of precocious puberty and among the causes of delayed puberty as well as a hormonal sleep test. Obstacles to making a timely diagnosis of disorders of puberty exist: 1) manufacturing cut-backs for low-profit drugs lead to frequent unavailability of natural GnRH (Factrel) for testing purposes, 2) childhood norms and diagnostic criteria have not been established for the current generation of highly sensitive and specific gonadotropin and sex steroid assays, and 3) scientific advances have led to potential new diagnostic outcome measures. This project compares children with disorders of puberty with healthy childhood controls. Primary outcome measures are the mean LH response to sleep in comparison to the LH peak response to the GnRHag leuprolide acetate.